Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
55 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Pipeline Review, H2 2014', provides an overview of the Acid Sphingomyelinase Deficiency (Niemann-Pick Disease)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Overview 7 Therapeutics Development 8 Pipeline Products for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Overview 8 Pipeline Products for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Comparative Analysis 9 Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Therapeutics under Development by Companies 10 Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Therapeutics under Investigation by Universities/Institutes 11 Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Products under Development by Companies 14 Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Products under Investigation by Universities/Institutes 15 Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Companies Involved in Therapeutics Development 16 Genzyme Corporation 16 La Jolla Pharmaceutical Company 17 Merck & Co., Inc. 18 Okklo Life Sciences BV 19 Orphazyme ApS 20 Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Therapeutics Assessment 21 Assessment by Monotherapy Products 21 Assessment by Combination Products 22 Assessment by Target 23 Assessment by Mechanism of Action 25 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Drug Profiles 31 arimoclomol - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 cyclodextrins + delta-tocopherol - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 GZ-402665 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 LJPC-0712 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 ML-SA1 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 OKL-1014 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 OR-0005 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Small Molecule to Target Cholesterol for Niemann-Pick Disease Type C - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Stem Cell Therapy for Cancer, Pain, Retinal Degeneration and Niemann-Pick Disease - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 vorinostat - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Recent Pipeline Updates 45 Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Dormant Projects 47 Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Product Development Milestones 48 Featured News & Press Releases 48 Jul 17, 2013: La Jolla Pharmaceutical Company Receives Orphan Designation From FDA 48 Apr 03, 2013: Old Drug Offers New Treatment For Niemann-Pick Type C, Study Finds 48 Feb 21, 2013: Orphazyme Receives Orphan Drug Designation For OR0005 In EU 50 Jan 23, 2013: NIH Clinical Trial Begins For Treatment Of Niemann-Pick Disease Type C1 50 Mar 13, 2012: U-M biologists Find Potential Drug That Speeds Cellular Recycling 51 Sep 19, 2001: Recombinant Human Acid Sphingomyelinase For The Treatment Of Niemann-Pick Disease, Type B Receives Orphan Drug Designation From Committee For Orphan Medicinal Products 53 Appendix 54 Methodology 54 Coverage 54 Secondary Research 54 Primary Research 54 Expert Panel Validation 54 Contact Us 55 Disclaimer 55
List of Tables Number of Products under Development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease), H2 2014 8 Number of Products under Development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Comparative Analysis, H2 2014 9 Number of Products under Development by Companies, H2 2014 10 Number of Products under Investigation by Universities/Institutes, H2 2014 11 Comparative Analysis by Clinical Stage Development, H2 2014 12 Comparative Analysis by Early Stage Development, H2 2014 13 Products under Development by Companies, H2 2014 14 Products under Investigation by Universities/Institutes, H2 2014 15 Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Pipeline by Genzyme Corporation, H2 2014 16 Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Pipeline by La Jolla Pharmaceutical Company, H2 2014 17 Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Pipeline by Merck & Co., Inc., H2 2014 18 Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Pipeline by Okklo Life Sciences BV, H2 2014 19 Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Pipeline by Orphazyme ApS, H2 2014 20 Assessment by Monotherapy Products, H2 2014 21 Assessment by Combination Products, H2 2014 22 Number of Products by Stage and Target, H2 2014 24 Number of Products by Stage and Mechanism of Action, H2 2014 26 Number of Products by Stage and Route of Administration, H2 2014 28 Number of Products by Stage and Molecule Type, H2 2014 30 Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Therapeutics - Recent Pipeline Updates, H2 2014 45 Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Dormant Projects, H2 2014 47
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
